NY-ESO-1

NY-ESO-1 is a cancer-testis antigen and immunotherapeutic target that is overexpressed in triple negative breast cancer (TNBC), where it has been evaluated for clinical relevance. In a systematic review/meta-analysis, expression was reported across 12 studies including 1,545 TNBC patients, with a pooled prevalence of 16.1% (PMID:41846058). Its main functional relevance is as an antigenic target rather than a signaling protein, making it useful for immune-based strategies such as vaccines and adoptive cell therapy. The literature also notes that histone deacetylase inhibitors and hypomethylating agents can upregulate NY-ESO-1 expression, potentially increasing tumor visibility to the immune system. Structural work has further defined T cell receptor recognition of the NY-ESO-1 157-165 epitope, supporting rational immunotherapy design. Overall, NY-ESO-1 is being developed as a biomarker and target in TNBC immunotherapy, with expression modulation and epitope-specific recognition as key advances.

Triple-negative breast cancer

  • NY-ESO-1 is overexpressed in triple negative breast cancer and discussed as an immunotherapeutic target in a 2026 systematic review/meta-analysis (PMID:41846058).
  • Across 12 studies and 1,545 TNBC patients, pooled NY-ESO-1 expression prevalence was 16.1%, indicating a measurable but not universal target population (PMID:41846058).
  • The review highlights clinical relevance for antigen-directed approaches in TNBC, including patient selection for immune-based therapies (PMID:41846058).
  • NY-ESO-1-targeted adoptive cell therapy is discussed as a therapeutic approach for this disease context (PMID:41846058).
  • NY-ESO-1-targeted peptide vaccines are also discussed as a therapeutic strategy in TNBC (PMID:41846058).

Immunotherapy and antigen modulation

  • histone deacetylase inhibitors can upregulate NY-ESO-1 expression, suggesting a mechanism to enhance antigen presentation and immunogenicity (PMID:41846058).
  • hypomethylating agents can also upregulate NY-ESO-1 expression, supporting epigenetic priming strategies before immunotherapy (PMID:41846058).
  • Structural analyses describe NY-ESO-1 157-165 recognition by t cell receptor, providing epitope-level insight for TCR-based therapies (PMID:41846058).
  • These findings support combining epigenetic modulators with NY-ESO-1-directed immune interventions to improve target availability (PMID:41846058).